These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 16728684

  • 1. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 2. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 3. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.
    Cochrane Database Syst Rev; 2014 Oct 23; 2014(10):CD007744. PubMed ID: 25340915
    [Abstract] [Full Text] [Related]

  • 4. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 23; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

  • 5. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 6. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 7. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.
    Arthritis Res Ther; 2005 Jun 27; 7(2):R333-42. PubMed ID: 15743481
    [Abstract] [Full Text] [Related]

  • 8. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M, Rahme E, Richard H, Pilote L.
    Arthritis Rheum; 2007 Apr 15; 57(3):516-23. PubMed ID: 17394181
    [Abstract] [Full Text] [Related]

  • 9. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM, Lévesque LE, Zhang B.
    Heart; 2007 Feb 15; 93(2):189-94. PubMed ID: 16849374
    [Abstract] [Full Text] [Related]

  • 10. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.
    Clin Ther; 2010 Jul 15; 32(7):1294-303. PubMed ID: 20678677
    [Abstract] [Full Text] [Related]

  • 11. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr 15; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 12. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Apr 15; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 15; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 14. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
    Lévesque LE, Brophy JM, Zhang B.
    CMAJ; 2006 May 23; 174(11):1563-9. PubMed ID: 16670396
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 23; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May 23; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 17. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep 23; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 18. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 19. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2005 May 09; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 20. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LT.
    Arthritis Care Res (Hoboken); 2015 Aug 09; 67(8):1137-49. PubMed ID: 25623277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.